A collection of landmark papers relevant to anaesthesia and anesthesiology.
Generally, these papers are practice changing and hold current, ongoing significance beyond their historical importance.
This is a dynamic and changing document that will be updated, pruned and added to as appropriate. Many of these papers have free full-text provided by the publisher because of their significance.summary
The potential for dexamethasone and other glucocorticoids to prolong peripheral nerve blocks was first noted almost 20 years ago.
While the effect has been observed with several different blocks (upper & lower extremity, and even TAP blocks), the clinical significance varies and several questions still remain:
Is the effect exclusive to perineural dexamethasone? Several studies have observed similar effects for both IV and perineural dexamethasone (though less profound than other papers).
Is the effect safe? This is perhaps the most concerning, as there are suggestions that the effect may represent an enhancement of the well-known neurotoxicity of local anaesthetic agents.
An extensive collection of research debunking a range of myths and misconceptions regarding the way we use neuromuscular blocking drugs.
- Myth 1: Modern relaxants are so reliable and predictable that monitoring is unnecessary.
- Myth 2: Post-op residual paralysis is neither common or important.
- Myth 3: Post-op residual paralysis is easy to identify.
- Myth 4: Sugammadex makes residual paralysis a non-issue. (it might, but only if it is routinely available and used!)
- Myth 5: Using propofol and remifentanil we can avoid relaxants for intubation all together.
- Myth 6: Neuromuscular blockade has no effect on BIS.
And bonus myth: deep relaxation is necessary for improving surgical access during laparoscopy.summary
...and 1 more note
Possibly... but with some important caveats.
“Sugammadex is likely the most exciting drug in clinical neuromuscular pharmacology since the introduction of atracurium and vecuronium in the middle 1980s.” – RD Miller (2007).
Sugammadex (Bridion®) is a remarkable drug – and the anaesthesia community has moved very quickly to embrace the potential of this first ‘selective relaxant binding agent’ (SRBA), despite it’s considerable cost.
Sugammadex offers a new and improved way of reversing aminosteroid muscle relaxation, in particular from rocuronium. The speed at which it reverses even profound neuromuscular blockade is incredible and potentially life saving. Sugammadex’s onset is 10 times faster than neostigmine and three times faster than edrophonium.
Though beyond the parlour-trick of speedy action, or the possibility of rescuing a cannot-intubate-cannot-ventilate crisis – the biggest benefit of sugammadex for our patients may be in the dramatic reduction of post-operative residual paralysis. A common problem with serious consequences that the anaesthetic community has ignored for far too long.summary
...and 2 more notes
The association of anesthesia in the sitting beach-chair position with intra-operative stroke, continues to be controversial. Although some studies have identified this as a risk, it is still a rare complication, albeit devastating.
Expert opinion suggests intra-arterial blood pressure monitoring is best practice, but most importantly with consideration for actual cerebral perfusion pressure given the sitting position.
Some research suggests regional anaesthesia, possibly combined with spontaneous ventilation GA (rather than relaxation GA with IPPV) offers unique benefits that better maintain cerebral oxygenation, although the exact difference is unclear.
Similarly, the benefit and role of non-invasive cerebral perfusion monitoring has not been conclusively shown, although it appears logical that it may offer benefit in these patients.
Case studies of patients suffering cerebral ischaemia under beach-chair, do point to combinations of poor intra-operative blood pressure management and possibly pre-existing mild cardiovascular disease (eg. hypertension) as contributing to some degree.summary